This tumor is aggressive and needs treatment, or this one is so slow-growing it will never harm you.
PET/TC with PSMA imaging makes cancer cells visible as bright spots, allowing doctors to distinguish aggressive tumors from slow-growing, low-risk ones. The PRIMARY2 trial showed the technique eliminated biopsies for patients without cancer or with very slow-growing tumors, reducing unnecessary procedures.
- PET/TC with PSMA imaging could reduce prostate biopsies by 50% without losing diagnostic accuracy
- PRIMARY2 trial tracked 660 patients over two years across Australia
- Technology makes cancer cells visible as bright points on scan, distinguishing aggressive from slow-growing tumors
- Already in use in UK and several European countries, but limited by cost and availability
An international study demonstrates that PET/TC imaging with PSMA can reduce unnecessary prostate biopsies by 50% while maintaining diagnostic accuracy, potentially avoiding overtreatment of low-risk tumors.
A man sits in a doctor's office and hears the word biopsy. His stomach tightens. The procedure means needles, tissue samples, days of worry waiting for results—all because an MRI came back unclear or suspicious. It's a familiar anxiety in urology clinics around the world. But an international research team may have found a way to spare thousands of patients from that experience.
Scientists at Peter MacCallum Cancer Centre in Melbourne and St Vincent Hospital in Sydney have demonstrated that a new imaging technique could cut the number of prostate cancer biopsies in half without sacrificing diagnostic accuracy. The findings come from the PRIMARY2 clinical trial, presented this month at the European Association of Urology congress in London. The technology uses a molecule that binds to prostate cancer cells, making them glow like bright points on a PET/TC scan—a visualization so clear that doctors can now distinguish between tumors that demand treatment and those that pose minimal threat.
The mechanism is elegant in its simplicity. When the PSMA-targeting agent attaches to cancer cells, those cells become luminous on the imaging screen. Dr. James Buteau, a nuclear medicine physician at Peter MacCallum, describes the effect as remarkable: aggressive cancers light up with particular intensity, a clarity he says is rare to see in routine clinical practice. This visibility allows specialists to separate patients who genuinely need intervention from those whose tumors grow so slowly they may never cause harm.
The trial enrolled people at elevated risk for prostate cancer—many with family histories of the disease—who had received normal results on magnetic resonance imaging. Ordinarily, these patients would still undergo biopsy as a precautionary measure. Researchers divided participants into two groups: some received the standard biopsy, others the new PET/TC scan with PSMA. The results told a striking story. The imaging technique identified patients without cancer entirely, and others whose tumors were so indolent they would likely never progress. For these individuals, biopsy proved unnecessary. Those whose scans showed genuine concern then underwent biopsy in a more targeted way, with doctors knowing exactly where to look.
The implications extend beyond convenience. Prostate cancer suffers from a well-documented problem: overdiagnosis. Doctors find slow-growing tumors that would never threaten a patient's life, then treat them aggressively anyway. The result is unnecessary surgery, radiation, or hormone therapy—interventions that carry real side effects and diminish quality of life for no medical benefit. Buteau notes that overdiagnosis at best leads to needless treatment, at worst to harm from procedures a patient never required. By identifying which cancers carry genuine risk, this imaging approach could spare men from that cascade of unnecessary care.
The PRIMARY2 trial is tracking 660 patients over two years, gathering evidence on how reliably this technology performs in practice. The scan is already in use across the United Kingdom and several European countries for detecting high-risk or recurrent prostate cancer, though cost and availability remain significant barriers. Most health systems have not yet adopted it widely. If that changes—if the technology becomes more accessible and affordable—it could reshape how doctors approach prostate cancer screening entirely. For now, the study offers something rarer: a diagnostic advance that doesn't just find more disease, but finds it smarter, sparing patients unnecessary procedures and the anxiety that comes with them.
Notable Quotes
The tomography PET/TC with PSMA illuminates prostate cancer cells remarkably, especially in more aggressive cancers. It is rare to see such powerful images in clinical practice.— Dr. James Buteau, nuclear medicine physician, Peter MacCallum Cancer Centre
Overdiagnosis of prostate cancer leads at best to unnecessary treatments and at worst to harmful procedures for cancers that would never cause damage.— Dr. James Buteau
The Hearth Conversation Another angle on the story
Why does a normal MRI result still lead to biopsy? Doesn't that seem redundant?
It does, but the fear of missing something drives the practice. MRI can be inconclusive—a shadow that might be cancer, might be nothing. Doctors err on the side of caution, especially with prostate cancer, because early detection matters. But that caution has a cost.
And this new scan changes that calculation?
It does something more precise. It doesn't just say yes or no to cancer. It says: this tumor is aggressive and needs treatment, or this one is so slow-growing it will never harm you. That distinction is everything.
So doctors can finally say to a patient: you have cancer, but you don't need surgery?
Exactly. And that's radical in oncology. We've been trained to treat everything we find. This scan lets us be selective, which paradoxically makes us better doctors.
What's stopping hospitals from using it everywhere right now?
Money and infrastructure. The scan requires specialized equipment and trained technicians. It's not available in most places yet. But if it becomes standard, the calculus of prostate cancer care shifts entirely.
For the patient sitting in that doctor's office, what does this mean?
It means fewer needles, less anxiety, and a clearer answer about whether their cancer is something to fear or something to watch. That's not a small thing.